The right option depends on the patients health history, BMI, metabolic markers, current medication, and treatment goals
Higa-Sansone G, Szomstein S, Soto F, et al
In recent years, two classes of glucose-lowering medications,sodium-glucose cotransporter 2 inhibitors (SGLT2-I) and glucagon-like peptide-1 receptor agonists (GLP-1RA),have emerged as cornerstone therapies due to their robust cardiovascular and renal protective effects
For instance, when tirzepatide was removed from the list in late 2024, it effectively shut down the compounding market, creating a massive vacuum for legal 505(b)(2) alternatives
Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized, double-blind, active control trial(*)
6B) compared to those of the rats in non-diabetic group (Fig